Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression.
|
19351822 |
2009 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Medulloblastomas have losses of 17p and most cases with dmins have c-myc gene amplification.
|
2192793 |
1990 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
C-MYC expression in medulloblastoma and its prognostic value.
|
11008200 |
2000 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma.
|
11489822 |
2001 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
c-Myc promoter activation in medulloblastoma.
|
12941792 |
2003 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients.
|
21324178 |
2011 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma.
|
23578955 |
2013 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A Proteogenomic Approach to Understanding MYC Function in Metastatic Medulloblastoma Tumors.
|
27775567 |
2016 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation.
|
16478988 |
2006 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Additional analysis by interphase fluorescence in situ hybridisation (iFISH), PCR-based mapping and SNP-array revealed this novel amplification at 8q24.22-q24.23 is independent of MYC amplification at 8q24.21, and is unique to medulloblastoma in over 800 cancer cell lines assessed from different tumour types, suggesting it contains key genes specifically involved in medulloblastoma development.
|
19584924 |
2009 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Amplification of the MYCN is the predominant marker for aggressive NB and correlates with poor prognosis, while c-MYC overexpression is a defining feature of MB subgroups inflected with aggressive biological behavior and increased likelihood of metastasis.
|
26373717 |
2016 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Amplifications in this series included MYCL, MYCN and MYC previously implicated in medulloblastoma pathogenesis, as well as novel amplicons on chromosomes 2, 4, 11 and 12.
|
17465989 |
2007 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both anaplasia and increased c-myc gene expression have been shown to be negative prognostic indicators for survival in medulloblastoma patients. myc gene amplification has been identified in many large cell/anaplastic medulloblastoma, but no causative link between c-myc and anaplastic changes has been established.
|
16423996 |
2006 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Both anaplasia and increased c-myc gene expression have been shown to be negative prognostic indicators for survival in medulloblastoma patients. myc gene amplification has been identified in many large cell/anaplastic medulloblastoma, but no causative link between c-myc and anaplastic changes has been established.
|
16423996 |
2006 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combined functional genomic and chemical screens identify SETD8 as a therapeutic target in MYC-driven medulloblastoma.
|
30626740 |
2019 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Critically, G207 delivered to the cerebellum was able to target/treat the highly aggressive MYC-overexpressed group 3 murine medulloblastoma increasing survival vs controls.
|
30918335 |
2019 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
DiSCoVER analysis predicted that aggressive MYC-driven Group 3 medulloblastoma would be sensitive to cyclin-dependent kinase (CDK) inhibitors.
|
27012813 |
2016 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression and association between PRMT5 and MYC in primary medulloblastoma tumors were investigated using publicly available databases.
|
31694585 |
2019 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, the positive correlation of MYC and JAG2 also with aggressive anaplastic tumors and highly metastatic MB stages suggested that high JAG2 expression may be useful as additional marker to identify aggressive MBs.
|
24708907 |
2014 |
Medulloblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Focal high-level amplifications of MYC (or MYCC) define a subset of high-risk medulloblastoma patients.
|
22160402 |
2012 |
Medulloblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
For pediatric CNS neoplasms, only medulloblastoma has been investigated in adequate numbers; a small percentage exhibit amplification of either the N-myc or c-myc genes.
|
1374522 |
1992 |
Medulloblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Functional analysis of enriched pathways highlighted cell-cycle progression and protein synthesis as therapeutic targets for MYC-like medulloblastoma.
|
29562177 |
2018 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, combination therapy with S3-NTDi and cisplatin significantly decreased highly aggressive MYC-amplified MB cell growth and induced apoptosis by downregulating STAT3 regulated proliferation and anti-apoptotic gene expression.
|
29280516 |
2018 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
GLI1 transcript was expressed in medulloblastomas with ATOH1 transcript, whereas high levels of MYC transcript were unrelated to NEUROG1 or ATOH1 expression.
|
17522332 |
2007 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we review the relationship of MYC family proteins to the four molecularly distinct medulloblastoma subgroups, discuss the possible roles MYC plays in each of these subgroups and in the developing cells of the posterior fossa, and speculate on possible therapeutic strategies targeting MYC.
|
24186490 |
2013 |